In part 3 of a discussion with Andrew Kuykendall, MD, Moffitt Cancer Center, he talks of rusfertide’s ability to enable ...

For patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation (allo-HCT), machine learning (ML) ...

Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.

Content sponsored by Incyte Imagine living with a chronic condition, with symptoms that can be subtle and difficult to ...

and polycythemia vera (PV) after long-term treatment (>12 months). IFN-α2 induces sustained major or complete molecular remissions in a subset of PV patients with normalization of the bone marrow ...

Three other Bay Area companies — Mirum Therapeutics Inc. (Nasdaq: MIRM), Soleno Therapeutics Inc. (Nasdaq: SLNO) and Exelixis ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Learn more about whether Corcept Therapeutics Incorporated or Novartis AG is a better investment based on AAII's A+ Investor ...

Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been given a consensus recommendation of “Hold” by the nineteen ...

Discover the connection between blood disorders and cancer development, plus the 5 key signs that require immediate medical ...